Oligo-Recurrence in Lung Cancer; The Most Curable State Among Advanced Disease?

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2024-12-06 DOI:10.3390/cancers16234086
Yoshihisa Shimada
{"title":"Oligo-Recurrence in Lung Cancer; The Most Curable State Among Advanced Disease?","authors":"Yoshihisa Shimada","doi":"10.3390/cancers16234086","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the introduction of effective systemic therapies and advancements in precision medicine, recurrence or progression remains common in advanced non-small cell lung cancer (NSCLC). For a subset of patients with more localized metastatic disease-referred to as oligometastases and oligo-recurrence-emerging evidence suggests that a multimodal approach combining systemic therapy with local ablative therapies (LATs) may offer curative potential. Oligo-recurrence is defined by the presence of a limited number of metastases and recurrences in patients with controlled primary lesions. In this review, we focus on providing a comprehensive overview of the evidence supporting the concepts of oligo-recurrence in lung cancer, which is considered one of the most curable states among advanced diseases. Although the definition remains variable and is still under discussion, retrospective studies have reported that it is not a rare condition (occurring in 18-53% of cases) and shows relatively better survival outcomes regardless of whether a local ablative therapy (LAT) is performed. However, this classification remains a topic of ongoing debate and warrants further exploration. In addition to an ongoing randomized clinical trial on oligo-recurrent NSCLC, further rigorous studies specifically addressing oligo-recurrence are needed to refine treatment strategies for this advanced yet potentially curable state. These investigations are essential for developing effective, tailored approaches to optimize outcomes for patients within this prognostically favorable subgroup.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"16 23","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16234086","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the introduction of effective systemic therapies and advancements in precision medicine, recurrence or progression remains common in advanced non-small cell lung cancer (NSCLC). For a subset of patients with more localized metastatic disease-referred to as oligometastases and oligo-recurrence-emerging evidence suggests that a multimodal approach combining systemic therapy with local ablative therapies (LATs) may offer curative potential. Oligo-recurrence is defined by the presence of a limited number of metastases and recurrences in patients with controlled primary lesions. In this review, we focus on providing a comprehensive overview of the evidence supporting the concepts of oligo-recurrence in lung cancer, which is considered one of the most curable states among advanced diseases. Although the definition remains variable and is still under discussion, retrospective studies have reported that it is not a rare condition (occurring in 18-53% of cases) and shows relatively better survival outcomes regardless of whether a local ablative therapy (LAT) is performed. However, this classification remains a topic of ongoing debate and warrants further exploration. In addition to an ongoing randomized clinical trial on oligo-recurrent NSCLC, further rigorous studies specifically addressing oligo-recurrence are needed to refine treatment strategies for this advanced yet potentially curable state. These investigations are essential for developing effective, tailored approaches to optimize outcomes for patients within this prognostically favorable subgroup.

肺癌寡复发;晚期疾病中最易治愈的状态?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信